Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends. Maxim Growth Summit in New York: Brian M. Strem, PhD, President and CEO, will speak on an ophthalmology panel titled "A vision of innovation" on October 22, 2025 at 3:00 PM EDT (panel overview link: maximgrp.com/2025-growth-summit).

Eyecelerator @ AAO 2025 in Orlando: Eric Daniels, MD, MBA, Chief Development Officer, will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT (program link: eyecelerator.com/aao-2025-program).

Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando.

Maxim Growth Summit Ophthalmology Panel Details

Title: A vision of innovation; Advances in biotechnology have spurred innovation in the management of diseases affecting our most used sense
Presenter: Brian M. Strem, PhD, President and Chief Executive Officer
Date & Time: October 22, 2025 at 3:00 pm EDT
More Details: maximgrp.com/2025-growth-summit

Eyecelerator @ AAO 2025 Presentation Details

Session: Poster Retina Showcase
Presenter: Eric Daniels, MD, MBA, Chief Development Officer
Date & Time: October 16, 2025 at 1:45 pm EDT
More Details: eyecelerator.com/aao-2025-program

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contact:

investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270410

FAQ

When will Kiora Pharmaceuticals (KPRX) present at Eyecelerator @ AAO 2025?

Kiora will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT.

Who is representing Kiora (KPRX) on the Maxim Growth Summit ophthalmology panel?

Brian M. Strem, PhD, President and CEO, will represent Kiora on the panel on October 22, 2025 at 3:00 PM EDT.

What topics will Kiora (KPRX) cover at the Maxim Growth Summit and AAO events?

Kiora will discuss its development pipeline and ophthalmology innovation, including a panel talk and a poster retina showcase.

Where can investors find details about Kiora's Maxim Growth Summit appearance (KPRX)?

Event details are listed at maximgrp.com/2025-growth-summit, including the panel title and schedule.

Where can investors access the Eyecelerator @ AAO 2025 program for Kiora's presentation (KPRX)?

Program details and session timing are available at eyecelerator.com/aao-2025-program.

Do these Kiora (KPRX) presentations include new clinical or financial data?

The announcements indicate company overviews and a poster showcase; no specific clinical or financial results are disclosed in the event listings.